Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Sartorius vz. Aktie 346908 / DE0007165631

16.02.2026 10:36:53

EQS-News: Sartorius sharpens climate targets and receives validation from Science Based Targets initiative

EQS-News: SARTORIUS AG / Key word(s): Sustainability/ESG
Sartorius sharpens climate targets and receives validation from Science Based Targets initiative (news with additional features)

16.02.2026 / 10:36 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, Germany | February 16, 2026

Sartorius sharpens climate targets and receives validation from Science Based Targets initiative
 
  • Ambitious new medium-term targets set for Scopes 1, 2, and 3
  • SBTi confirms compatibility of science-based reduction targets with Paris Climate Agreement
  • Long-term ambition remains unchanged: net-zero greenhouse gas emissions by 2045

The life science group Sartorius has sharpened its medium-term climate targets and received validation from the Science Based Targets initiative (SBTi). The organization confirmed that the new greenhouse gas reduction targets are in line with the Paris Climate Agreement.

“We have refined our climate targets and, with SBTi validation, taken an important step that is increasingly expected in our industry: science-based targets aligned with the United Nations’ decarbonization pathways. This underscores our level of ambition,” said Sartorius CEO Dr. Michael Grosse. “At the same time, we are turning ambition into action: We are transitioning our sites to renewable energy, working closely with customers and suppliers to advance the use of low-emission materials and processes, and applying eco-design principles to a growing share of our product portfolio. This is how we reduce our own footprint and help our customers achieve their sustainability goals.”

For direct emissions from its own operations and vehicle fleet, as well as indirect emissions from purchased energy - Scopes 1 and 2 -, Sartorius aims to reduce CO2 equivalents in metric tons by 42 percent by 2030 compared with the base year 2022. The target now covers all relevant emission sources and exceeds the 95 percent coverage required by the Science Based Targets initiative. According to SBTi criteria, it is therefore aligned with the United Nations’ 1.5-degree Celsius target. The most important lever for reducing Scope 1 and 2 emissions at Sartorius remains the global transition of sites to renewable energy. An increasing number of facilities are to source electricity from renewable sources and heat, cooling, and steam is also planned to be generated sustainably.

For indirect emissions along the company’s value chain, the Sartorius Executive Board has defined an intensity target, assuming continued business growth: The company plans to reduce its Scope 3 emissions by 51.6 percent by 2030 compared to 2022 relative to the company’s value added1. The most important drivers are the decarbonization of the supply chain together with customers and suppliers, the eco-design of products and packaging, logistics, and sustainable building construction.

The company’s long-term climate ambition remains unchanged: Sartorius aims to have a climate-neutral value chain by 2045 and achieve net-zero greenhouse gas emissions by eliminating all avoidable emissions and offsetting the remaining ones.

The updated climate targets remain part of the long-term remuneration components of the Executive Board and replace the previous ones.
Learn more: www.sartorius.com/sustainability
A profile of Sartorius
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.

Visit our newsroom and follow us on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com

Additional features:

File: 20260216_SAG_Media Release_Sartorius sharpens climate targets_en
File: Photo_Sartorius Campus in Göttingen


16.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: SARTORIUS AG
Otto-Brenner-Strasse 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2276308

 
End of News EQS News Service

2276308  16.02.2026 CET/CEST

Analysen zu Sartorius AG Vz.

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
11.02.26 Sartorius vz. Overweight JP Morgan Chase & Co.
05.02.26 Sartorius vz. Buy Deutsche Bank AG
04.02.26 Sartorius vz. Buy Deutsche Bank AG
04.02.26 Sartorius vz. Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
04.02.26 Sartorius vz. Buy Jefferies & Company Inc.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Dienstag 18 Uhr live: Der Preis ist das Ergebnis - so liest du Volumen und Orderflow richtig

Das Webinar am Dienstagabend mit Uwe Kälberer zeigt, wie Volumen und Orderflow offenlegen, wo Kapital agiert - und warum Märkte laufen, stoppen oder täuschen.

Schnell Plätze sichern!

Dividenden Könige – Was macht sie besonders? – Wallstreet Live mit Tim Schäfer

In dieser Ausgabe von BX Swiss TV sprechen David Kunz und Tim Schäfer über ein besonders spannendes Thema für langfristige Anleger: Dividendenkönige – also Unternehmen, die ihre Dividende seit mindestens 50 Jahren jährlich steigern!

Was erwartet euch in dieser Folge?
✔️ Definition: Was macht eine Aktie zum Dividendenkönig?
✔️ Stabile Klassiker wie Johnson & Johnson, Coca-Cola, Procter & Gamble oder Colgate-Palmolive
✔️ Kontroverse Top-Performer wie Altria – die „beste Aktie der letzten 100 Jahre“
✔️ Unbekannter Star: Federal Realty Investment Trust
✔️ Target – ein Dividendenkönig in der Krise
✔️ Chancen in der Schwäche: Value-Investing bei Qualitätsaktien

https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Dividenden Könige – Was macht sie besonders? Wallstreet Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 14’227.75 19.16 SNQBTU
Short 14’500.74 13.81 S8GBGU
Short 15’083.67 8.66 SYYBEU
SMI-Kurs: 13’663.48 16.02.2026 16:12:52
Long 13’100.35 19.71 S18BJU
Long 12’807.00 13.88 SFDBEU
Long 12’247.11 8.86 SH7B4U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com